NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Thanks for posting this dstock07734. It’s also interesting and noteworthy that the ATL-DC (DCVax-L) SPORE combination trial does not show that poly-ICLC is being included as a combination or as an adjuvant.

However, we know that poly-ICLC is being used, but it is automatically included in the ATL-DC (DCVax-L) as a component, and is part of the current formulation for ATL-DC (DCVax-L).

Dr. Prins graphically showed that poly-ICLC is now part of the DCVax-L preparation process, even though the poly-ICLC is administered separately as an intramuscular injection and the DCVax-L is administered as a separate, but concurrent intradermal injection.

The only combination treatments that are specifically mentioned are the PD-1 inhibitor Keytruda (Pembrolizumab) and the CSF-1R inhibitor, PLX3397.